Anteris Technologies Global (NASDAQ:AVR) Earns “Overweight” Rating from Cantor Fitzgerald

Anteris Technologies Global (NASDAQ:AVR)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a research note issued on Wednesday, Benzinga reports. They presently have a $15.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 139.62% from the company’s current price.

A number of other equities research analysts have also recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Barclays raised shares of Anteris Technologies Global to a “hold” rating in a research note on Wednesday, October 7th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $14.00.

Anteris Technologies Global Trading Down 2.9%

Shares of Anteris Technologies Global stock traded down $0.19 during trading hours on Wednesday, reaching $6.26. 1,739,979 shares of the company’s stock were exchanged, compared to its average volume of 1,124,172. The company has a 50 day moving average of $8.32 and a two-hundred day moving average of $8.05. Anteris Technologies Global has a fifty-two week low of $3.30 and a fifty-two week high of $11.06. The stock has a market cap of $610.10 million, a P/E ratio of -3.21 and a beta of 1.87.

Anteris Technologies Global (NASDAQ:AVR) last released its earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. The company had revenue of $1.01 million during the quarter, compared to analyst estimates of $1.50 million. During the same period in the prior year, the firm posted ($0.58) EPS. As a group, analysts expect that Anteris Technologies Global will post -1.21 earnings per share for the current fiscal year.

Insider Activity

In other Anteris Technologies Global news, major shareholder L1 Capital Pty Ltd purchased 272,695 shares of Anteris Technologies Global stock in a transaction that occurred on Tuesday, October 6th. The stock was acquired at an average price of $7.18 per share, for a total transaction of $1,957,950.10. Following the completion of the acquisition, the insider owned 6,358,271 shares of the company’s stock, valued at approximately $45,652,385.78. This trade represents a 4.48% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Over the last quarter, insiders have bought 1,554,730 shares of company stock valued at $11,694,513 and have sold 3,008,459 shares valued at $25,243,576. Insiders own 4.50% of the company’s stock.

Institutional Trading of Anteris Technologies Global

A number of hedge funds have recently made changes to their positions in AVR. Cetera Investment Advisers increased its holdings in shares of Anteris Technologies Global by 64.7% in the first quarter. Cetera Investment Advisers now owns 16,550 shares of the company’s stock valued at $92,000 after purchasing an additional 6,500 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Anteris Technologies Global by 12.6% during the 1st quarter. Bank of America Corp DE now owns 68,755 shares of the company’s stock worth $382,000 after buying an additional 7,688 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Anteris Technologies Global during the 2nd quarter worth about $78,000. Bartlett & CO. Wealth Management LLC boosted its holdings in shares of Anteris Technologies Global by 174.5% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company’s stock worth $79,000 after buying an additional 8,200 shares during the period. Finally, Abel Hall LLC bought a new stake in shares of Anteris Technologies Global during the 1st quarter worth about $63,000.

About Anteris Technologies Global

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.